CorMedix Inc. (Nasdaq: CRMD) reported a change in its executive leadership structure effective June 29, 2026, creating a new senior role that expands oversight of the company’s commercial operations. The company’s board of directors appointed Elizabeth Hurlburt, who had been serving as Chief Operating Officer, to the newly created position of Chief Operating and Commercial Officer. In the expanded role, Hurlburt will oversee all commercial functions, in addition to her responsibilities covering medical affairs, regulatory matters and clinical functions. She will continue to report to Joseph Todisco, CorMedix’s Chairman and Chief Executive Officer. As part of the leadership restructuring, Michael Seckler has left the company. The filing does not provide further details on the circumstances of Seckler’s departure, any separation arrangements, or whether his responsibilities were reassigned beyond the expanded scope given to Hurlburt. The disclosure was made under Item 8.01, “Other Events,” of Form 8-K. The filing does not report any securities issuance, insider stock transaction, compensation grant, option award, vesting schedule, share count, transaction price, or change in ownership. Its significance is operational and governance-related: CorMedix is consolidating commercial, medical, regulatory and clinical oversight under Hurlburt while maintaining reporting lines to CEO Joseph Todisco.